Fountain Life, a preventative health and longevity company, has raised $15m in a recent funding round.
The round was led by investment firms such as Eos Venture Partners and Newcross Healthcare.
Fountain Life claims it is committed to transforming the current healthcare model and moving the emphasis from reactive to preventive care by using cutting-edge technology to detect asymptomatic diseases early.
The company has brought together some of the world’s leading and most innovative physicians and scientists to create a new kind of healthcare that is predictive, preventive, personalised, and data-driven.
By leveraging new AI technologies and advanced diagnostic testing to identify conditions such as cancer, cardiac, metabolic, and neurodegenerative disease at the earliest stages, Fountain Life gives members the information and tools to make lifestyle modifications that can help them live longer, happier lives.
According to Fountain Life, the investment will support the company, including its integrated insurance business, to transform the healthcare ecosystem while improving future healthcare and its availability in the home and more widely around the globe.
Fountain Life CEO and co-founder Bill Kapp said, “Detecting asymptomatic disease is challenging because the human body is amazing at masking symptoms, but diagnostic technologies have come a long way. The ability to screen for structural abnormalities and other key indicators of developing disease exists today, but we must change the healthcare delivery model to truly realize the benefits of early disease detection.
“The best way to avoid or mitigate long term issues is to look for them early – waiting until conditions manifest themselves and require costly treatment is suboptimal and can lead to reduced longevity and quality of life. We are humbled by the commitment by Eos Venture Partners and Newcross Healthcare to support this transformation.”
Copyright © 2022 FinTech Global
